A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
Status:
Terminated
Trial end date:
2017-04-26
Target enrollment:
Participant gender:
Summary
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as
OTX015) for further studies in participants with advanced nuclear protein in testis (NUT)
midline carcinoma (NMC), triple negative breast cancer (TNBC), non-small cell lung cancer
(NSCLC), or castration-resistant prostate cancer (CRPC). This is a two-part parallel study:
Part A will establish the recommended dose by evaluating dose limiting toxicity (DLT),
safety, discontinuation, and early efficacy and Part B will enroll participants with NMC only
and will evaluate safety and efficacy in this population.